How have VCNX shares performed in 2024?

Vaccinex's stock was trading at $9.3072 at the start of the year. Since then, VCNX shares have decreased by 46.0% and is now trading at $5.03. View the best growth stocks for 2024 here .

Are investors shorting Vaccinex?

Vaccinex saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,300 shares, a decline of 28.4% from the March 15th total of 8,800 shares. Based on an average daily volume of 12,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.2% of the company's shares are short sold. View Vaccinex's Short Interest .

When is Vaccinex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VCNX earnings forecast .

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($35.70) EPS for the quarter, beating the consensus estimate of ($60.90) by $25.20. The business earned $0.05 million during the quarter.

When did Vaccinex's stock split?

Vaccinex's stock reverse split on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV) , OPKO Health (OPK) , Aldeyra Therapeutics (ALDX) , Sorrento Therapeutics (SRNE) , Cerecor (CERC) , Exelixis (EXEL) , Pfizer (PFE) , AVEO Pharmaceuticals (AVEO) , Heat Biologics (HTBX) and SCYNEXIS (SCYX) .

When did Vaccinex IPO?

Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VCNX

Vaccinex (VCNX) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free VCNX Stock Alerts

$5.03

-1.07 (-17.54%)

(As of 04/15/2024 ET)

Compare

Today's Range: $4.84
▼
$5.91
50-Day Range: $5.03
▼
$12.25
52-Week Range: $4.84
▼
$100.80

Volume: 30,949 shs
Average Volume: 11,954 shs
Market Capitalization: $6.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Vaccinex alerts:

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Vaccinex Stock (NASDAQ:VCNX)

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

VCNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VCNX Stock News Headlines

April 14, 2024 | investing.com

Vaccinex faces Nasdaq compliance challenge

April 2, 2024 | investorplace.com

VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 2, 2024 | globenewswire.com

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

March 27, 2024 | globenewswire.com

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

March 6, 2024 | investing.com

Vaccinex CFO Scott Royer to retire, Jill Sanchez steps in

March 2, 2024 | morningstar.com

Vaccinex Inc VCNX

February 21, 2024 | finanznachrichten.de

Vaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

February 21, 2024 | markets.businessinsider.com

Vaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platform

February 21, 2024 | finance.yahoo.com

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

February 21, 2024 | globenewswire.com

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

February 15, 2024 | markets.businessinsider.com

Vaccinex Announces 1-For-14 Reverse Stock Split

February 15, 2024 | msn.com

Why Vaccinex (VCNX) Stock Is Trading Lower

February 15, 2024 | globenewswire.com

Vaccinex, Inc. Announces Reverse Stock Split

February 12, 2024 | finance.yahoo.com

Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc

February 8, 2024 | msn.com

Vaccinex Inc Secures $3.7M in Private Placement Deal

February 7, 2024 | msn.com

Why Vaccinex (VCNX) Stock Is Popping Off

February 7, 2024 | markets.businessinsider.com

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

December 4, 2023 | finance.yahoo.com

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

November 13, 2023 | finance.yahoo.com

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 31, 2023 | finance.yahoo.com

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

October 26, 2023 | finance.yahoo.com

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

October 6, 2023 | markets.businessinsider.com

Why Is Vaccinex (VCNX) Stock Up 26% Today?

September 29, 2023 | finanznachrichten.de

Vaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public Offering

September 29, 2023 | marketwatch.com

Vaccinex Shares Slide Premarket After Stock Offering

September 29, 2023 | finance.yahoo.com

Vaccinex Announces Pricing of $9.6 Million Public Offering

See More Headlines

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VCNX
CUSIP: N/A
CIK: 1205922
Web: www.vaccinex.com
Phone: (585) 271-2700
Fax: 585-271-2765
Employees: 38
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($100.8610)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,250,000.00
Net Margins: N/A
Pretax Margin: -3,552.81%
Return on Equity: -2,667.31%
Return on Assets: -571.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.57
Quick Ratio: 0.57

Sales & Book Value

Annual Sales: $570,000.00
Price / Sales: 10.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.59) per share
Price / Book: -1.94

Miscellaneous

Outstanding Shares: 1,230,000
Free Float: 598,000
Market Cap: $6.19 million
Optionable: Optionable
Beta: 0.74

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Maurice Zauderer Ph.D. (Age 78)
Co-Founder, CEO, President & Director
Comp: $400.7k
Dr. Elizabeth E. Evans Ph.D. (Age 52)
COO and Senior VP of Discovery & Translational Medicine
Comp: $255.46k
Dr. Ernest S. Smith Ph.D. (Age 52)
Senior VP of Research & Chief Scientific Officer
Comp: $284.02k
Ms. Jill Sanchez (Age 52)
Controller, Interim CFO, Principal Financial Officer & Principal Accounting Officer
Dr. John E. Leonard Ph.D. (Age 77)
Senior Vice President of Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed in 2024?: Vaccinex's stock was trading at $9.3072 at the start of the year. Since then, VCNX shares have decreased by 46.0% and is now trading at $5.03.
View the best growth stocks for 2024 here.
Are investors shorting Vaccinex?: Vaccinex saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,300 shares, a decline of 28.4% from the March 15th total of 8,800 shares. Based on an average daily volume of 12,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.2% of the company's shares are short sold.
View Vaccinex's Short Interest.
When is Vaccinex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our VCNX earnings forecast.
How were Vaccinex's earnings last quarter?: Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($35.70) EPS for the quarter, beating the consensus estimate of ($60.90) by $25.20. The business earned $0.05 million during the quarter.

When did Vaccinex's stock split?: Vaccinex's stock reverse split on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Vaccinex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).
When did Vaccinex IPO?: Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.
How do I buy shares of Vaccinex?: Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VCNX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial